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The insufficient standardization of diagnostic next-generation sequencing (NGS) still
limits its implementation in clinical practice, with the correct detection of mutations at
low variant allele frequencies (VAF) facing particular challenges. We address here the
standardization of sequencing coverage depth in order to minimize the probability of false
positive and false negative results, the latter being underestimated in clinical NGS. There
is currently no consensus on the minimum coverage depth, and so each laboratory has
to set its own parameters. To assist laboratories with the determination of the minimum
coverage parameters, we provide here a user-friendly coverage calculator. Using the
sequencing error only, we recommend a minimum depth of coverage of 1,650 together
with a threshold of at least 30mutated reads for a targeted NGSmutation analysis of≥3%
VAF, based on the binomial probability distribution. Moreover, our calculator also allows
adding assay-specific errors occurring during DNA processing and library preparation,
thus calculating with an overall error of a specific NGS assay. The estimation of correct
coverage depth is recommended as a starting point when assessing thresholds of NGS
assay. Our study also points to the need for guidance regarding the minimum technical
requirements, which based on our experience should include the limit of detection (LOD),
overall NGS assay error, input, source and quality of DNA, coverage depth, number of
variant supporting reads, and total number of target reads covering variant region. Further
studies are needed to define the minimum technical requirements and its reporting in
diagnostic NGS.
Keywords: next-generation sequencing, variant allele frequency (VAF), coverage depth calculator, sequencing
error, small subclones, TP53 gene
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INTRODUCTION
Next-generation sequencing (NGS) has rapidly expanded into
the clinical setting in haemato-oncology and oncology, as it
may bring great benefits for diagnosis, selection of treatment,
and/or prognostication for many patients (1). Recently, several
articles about the validation of deep targeted NGS in clinical
oncology were published (2, 3), including a comprehensive
recommendation by the Association for Molecular Pathology
and the College of American Pathologists (1). However, the lack
of standardization of targeted NGS methods still limits their
implementation in clinical practice (4).
One challenge in particular is the correct detection of
mutations present at low variant allele frequencies (VAF) and
standardization of sequencing coverage depth (1, 5, 6). This is
especially important for mutations that have clinical impacts
at subclonal frequencies (1) such as the case of TP53 gene
mutations (TP53mut) in chronic lymphocytic leukemia (CLL)
(7, 8). TP53 aberrations (TP53mut and/or chromosome 17p
deletion) are among the strongest prognostic and predictive
markers guiding treatment decisions in CLL (9). Nowadays, the
European Research Initiative on Chronic Lymphocytic Leukemia
(ERIC) recommends detecting TP53mut with a limit of detection
(LOD) of at least 10% VAF (10), and a growing body of evidence
exists dedicated to the clinical impact of small TP53 mutated
subclones in CLL (7, 8).
Sanger sequencing and deep targeted NGS are currently the
techniques most used for TP53mut analysis (10) as well as
for analysis of other genes with clinical impacts at low allele
frequencies. Although Sanger sequencing provides a relatively
accessible sequencing approach, it lacks the sensitivity needed to
detect subclones due to its detection limit of 10–20% of mutated
alleles (10). NGS-based analysis has thus gained prominence in
diagnostic laboratories for the detection of somatic variants and
various technical developments of error correction strategies,
both computational and experimental, are being developed
for the accurate identification of low-level genetic variations
(11). We therefore address the importance of the correct
determination of sequencing depth in diagnostic NGS in order
to obtain a confident and reproducible detection, not only of
low VAF variants. Finally, we performed a dilution experiment to
confirm our theoretical calculations, and we close by discussing
our experience with diagnostic detection of TP53mut in CLL
patients and further perspectives about NGS standardization in
cancer diagnostics.
NGS SEQUENCING DEPTH AND ERROR
RATE
NGS sequencing depth directly affects the reproducibility of
variant detection: the higher the number of aligned sequence
reads, the higher the confidence to the base call at a particular
position, regardless of whether the base call is the same as the
reference base or is mutated (1). In other words, individual
sequencing error reads are statistically irrelevant when they are
outnumbered by correct reads. Thus, the desired coverage depth
should be determined based on the intended LOD, the tolerance
for false positive or false negative results, and the error rate of
sequencing (1, 11).
Using a binomial distribution, the probability of false positive
and false negative results for a given error rate as well as the
intended LOD can be calculated, and the threshold for a variant
calling for a given depth can be estimated (1). For example,
given a sequencing error rate of 1%, a mutant allele burden
of 10%, and a depth of coverage 250 reads, the probability of
detecting 9 or fewer mutated reads is, according to the binomial
distribution, 0.01%. Hence, the probability of detecting 10 or
more mutated reads is 99.99% (100–0.01%), and the threshold
for a variant calling can be defined. In other words, a coverage
depth of 250 with a threshold of at least 10 mutated reads will
have a 99.99% probability that 10% of the mutant allele load will
not be missed by the variant calling (although it can be detected
in a different proportion). In this way, the risk of a false negative
result is greatly minimized. On the other hand, the probability
of false positives heavily depends on the sequencing error rate
(as the accuracy of all analytical measurements depends on the
signal-to-noise ratio) (1, 11). In our example, the probability
of a false positive result is 0.025%; however, the rate of false
positives is not negligible when decreasing the LOD to the
value close to the error rate. Conventional intrinsic NGS error
rates range between 0.1 and 1% (Phred quality score of 20–30)
(1, 11) depending on the sequencing platform, the GC content
of the target regions (12), and the fragment length, as shown in
Illumina paired-end sequencing (13). Therefore, the detection of
variants at VAFs <2% is affected by a high risk of a false positive
result, regardless of the coverage depth. It is also important to
mention that the sequencing error rate applies only for errors
produced by sequencing itself and does not include other errors
introduced during DNA processing and library preparation,
particularly during amplification steps, which further increase
error rates (1, 11).
MINIMUM SEQUENCING COVERAGE IN
CLINICAL SETTINGS
There is currently no consensus on the minimum required
coverage in a clinical setting using deep targeted resequencing
by NGS, and so each laboratory has to set its own parameters
in order to meet sufficient quality (1, 5). To date, only a few
studies have recommended the minimum coverage criteria for
deep targeted NGS in clinical oncology: 500 depth of coverage
and a LOD of 5% (2), 300–500 depth of coverage without defying
the LOD (3), 250 depth and a LOD of 5% with threshold
adjustment to 1,000 depth of coverage is required in cases of
heterogeneous variants in low tumor cellularity samples (1), and
100 depth with at least 10 variant reads and a LOD of 10%
(10). According to the binominal data distribution, a coverage
depth of 250 should indeed be sufficient to detect 5% VAF
with a threshold of variant supporting reads ≥5 (Figure 1).
On the other hand, NGS analysis with a coverage depth of
100 along with a requirement of at least 10 variant supporting
reads as recommended by the ERIC consortium (10) would
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FIGURE 1 | LOD as a function of coverage depth according to the binomial distribution. Coverage depth needed to maintain an intended LOD (within 3–20% VAF
range) for three cumulative probability settings: for false positive probability of 0.001 and true positive of 0.999, a LOD of 20% is achieved at 61 coverage depth, a
LOD of 10% at 175, a LOD of 5% at 562, and a LOD of 3% at 1,650. For the false positive probability of 0.010 and true positive of 0.990, a LOD of 20% is achieved at
31, a LOD of 10% at 81, a LOD of 5% at 288, and a LOD of 3% at 886 coverage depth, respectively. For the false positive probability of 0.050 and true positive of
0.950, a LOD of 20% is achieved at 30, a LOD of 10% at 30, a LOD of 5% at 124, and a LOD of 3% at 392 coverage depth, respectively.
result in a false negative of 45% for samples with a LOD of
10%. To confirm these theoretic calculations, we performed two
independent dilution experiments to estimate the performance of
TP53 NGS analysis to detect 10% VAF at a depth of coverage of
100 reads. Indeed, we detected 30% of false negatives (5 positive
samples of 7 true-positive samples and 9 positive samples of
13 true-positive samples) in two independent sequencing runs.
Unfortunately, the false negative rate is often underestimated
in targeted resequencing. Also, a recent study investigating
inter-laboratory results of somatic variant detection with VAFs
between 15 and 50% in 111 laboratories with reported LODs
of 5–15% (6) shows that major errors in diagnostic NGS may
arise from false negative results, even in samples with high
mutation loads (6). Of three concurrent false positive results, all
variants were correctly detected but mischaracterised (6). Since
laboratories have not been asked to report coverage depth for
other regions than the identified variants (6), wemay only assume
that low coverage or high variant calling thresholds contributed
to the false negative results. These results further highlight the
need for standardized coverage depth parameters in diagnostic
NGS, taking into account sequencing errors as well as assay-
specific errors.
FREQUENCY OF TP53 SUBCLONAL
MUTATIONS IN CLL DETECTED THROUGH
DIAGNOSTIC NGS
In order to evaluate the occurrence of low VAF in real-world
settings, we reviewed our cohort of CLL patients examined
for TP53mut in our diagnostic laboratory. The TP53mut were
assessed as reported previously (14, 15). Briefly, TP53 (exons 2–
10 including 2 bp intronic overlap, 5′ and 3′UTR) was analyzed
using 100 ng gDNA per reaction. Amplicon-based libraries
were sequenced as paired-end on MiSeq (2x151, Illumina) with
minimum target read depths of 5,000x. The LODofTP53mut was
set up to 1%, and the variants in the range 1–3% were confirmed
by replication. Written informed consent was obtained from
all the patients who were enrolled in accordance with the
Helsinki Declaration, and the study was approved by the local
ethical committee.
Of the diagnostic cohort of 859 CLL patients (April 2016–
April 2019), 25% (215/859) were positive for TP53mut, and of
those, 52.6% (113/215) carried variants with VAF at 10% or lower.
In line with our observations, a recent study (8) reported the
presence of 63 and 84% low burden (Sanger negative) TP53muts
in CLL patients at the time of diagnosis and at the time of
treatment, respectively, and confirmed the negative impact on
the overall survival of TP53muts above 1% VAF at the time of
treatment (8).
CALCULATOR FOR DIAGNOSTIC NGS
SETTINGS FOR DETECTION OF
SUBCLONAL MUTATIONS
To assist laboratories with the determination of the minimum
proper coverage parameters, we are providing a simple, user-
friendly theoretical calculator (software) based on the binomial
distribution (Figure 2), described in the Supplementary File. A
web (or desktop) application and stand-alone source codes in
R are accessible on Github: https://github.com/mvasinek/olgen-
coverage-limit. Using this calculator, the correct parameters of
sequencing depth and the corresponding minimum number of
variant reads for a given sequencing error rate and intended
LOD can easily be determined. Moreover, users can also take into
account other errors by simply adding assay-specific errors to the
sequencing error rate and using this overall error as an input
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FIGURE 2 | OLGEN Coverage Limit calculator—a simple theoretical calculator suitable for determining the correct sequencing depth and corresponding minimum
number of variant reads according to the binomial distribution for a given sequencing error rate and intended LOD recommended for diagnostic NGS. Examples of
calculated sequencing depths and the corresponding minimum number of variant reads recommended for variants with (A) 10% VAF and 99.9% probability of
detection and (B) 3% VAF and 99.9% probability of detection.
to the calculator. For example, in our case of TP53 mutational
analysis we calculated with the overall error of ∼1.16%, thus we
set up our minimum coverage depth requirements to 2,000 with
threshold of minimum 40 reads for 3% VAF.
DISCUSSION
Although diagnostic NGS has gained prominence in clinical
settings for the assessment of somatic mutations in cancer,
insufficient standardization of sequencing parameters still limits
its implementation in clinical practice (1), mainly for variants
present at low allele frequencies (4). We, therefore, addressed the
technical question of correctly determining the sequencing depth
in diagnostic NGS in order to obtain confident and reproducible
detections of low VAF variants. In particular, we performed
theoretical calculations to determine the optimum depth of
coverage for the desired probability of detection of variants at
low allele frequencies, taking into account the sequencing error
rate. Moreover, we confirmed these theoretical calculations by
conducting dilution experiments. Based on these observations,
we recommend a depth of coverage of 1,650 or higher (together
with the respective threshold of at least 30 mutated reads) to
call ≥3% variants to achieve a 99.9% probability of variant
detection, using the conventional NGS sequencing error only.
Variants in the 1–3% VAF range can only be called if the
obtained sequence data is of high quality (average Q30 >
90%) and/or when the variants are confirmed by replication
or the orthogonal method (1, 11, 16). We are also providing
a simple, user-friendly theoretical calculator (software) to assist
laboratories with resolving the correct sequencing depth and the
corresponding minimum number of variant reads while taking
into account the sequencing error rate. Our simple calculator
may help to minimize the false positive and false negative results
in diagnostic NGS.
Nevertheless, correct sequencing depth is also influenced by
assay-specific factors (1). Errors can occur at many stages during
DNA processing and library preparation. The most common are
amplification errors introduced during NGS library preparation
(1, 12, 17). Other common sources of errors have to do with
library complexity (the number of independent DNA molecules
analyzed), DNA quality, and target region complexity etc. All
potential assay-specific errors should be addressed through test
design, method validation, and quality control.
Currently, emerging error correction strategies, both
computational and experimental, are being developed in order
to mitigate the high error rates in diagnostic NGS (11). So
far, among the most promising error correction methods
are UMI (Unique Molecular Identifiers), which correct for
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PCR errors (18), and signal-to-noise correction approaches
(11). These advances attempt to reduce the LOD, thereby
increasing sequencing accuracy needed for future opportunities
in NGS diagnosis.
In order to improve the standardization in diagnostic NGS,
the estimation of correct coverage depth is a recommended
starting point when assessing thresholds surrounding a particular
NGS assay. Nevertheless, there is still lack of published guidance
regarding the minimum technical requirements and its reporting
in NGS, particularly important in detection of clonal and
subclonal mutations in cancer diagnostics. This is mainly due
to the broad range of library preparation approaches, and
numerous variables playing a role in each specific NGS assay,
that are difficult to standardize, together with inter-laboratory
variability. Therefore, the definition of minimum technical
requirements and its reporting in NGS is highly desirable. Based
on our experience in diagnostic NGS in haemato-oncology,
we suggest to report at least following technical parameters:
LOD, overall error of NGS assay (or at least sequencing
error rate), the amount of DNA input, source, and quality
of DNA, minimum coverage depth and the percentage of
targeted bases sequenced at this minimum depth, total number
of target reads covering variant region and number of reads
supporting the variant. Special emphasis should be given to NGS
standardization of the formalin-fixed paraffin-embedded (FFPE)
samples (19, 20).
Taken together, our study highlights the importance of correct
sequencing depth and the minimum number of reads required
for reliable and reproducible detection of variants with low
VAF in diagnostic NGS. The calculation of correct sequencing
depth for a given error rate using our user-friendly theoretical
calculator (software) may help to minimize the false positive
and false negative results in diagnostic NGS, in situations related
to subclonal mutations among others. The rigorous testing
and standardized minimum requirements for diagnostic NGS is
particularly desirable to ensure correct results in clinical settings.
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